Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Holding MYGN?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.03Last Year’s EPS
$0.04Same Quarter Last Year
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -25.47%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with strong revenue growth and strategic investments highlighting the company's performance. However, significant challenges were noted, particularly the potential revenue impact from UnitedHealthcare's policy change and slower growth in certain segments.Company Guidance
During the Myriad Genetics third quarter 2024 earnings call, the company provided guidance indicating a solid financial performance with an 11% year-over-year revenue growth, reaching approximately $840 million. They achieved $150 million in gross profits, $14 million in adjusted EBITDA, and a positive adjusted EPS of $0.06, while maintaining about $149 million in liquidity. Despite challenges, including a policy change from UnitedHealthcare affecting their GeneSight test, Myriad is targeting a 2024 adjusted EPS between $0.12 and $0.14. The company plans to mitigate potential revenue impacts through cost-saving measures and expects to continue its double-digit growth trajectory, focusing on expanded product offerings and operational efficiencies.Strong Quarterly Performance
Achieved 11% revenue growth compared to last year, with $150 million in gross profits, $14 million of adjusted EBITDA, and positive adjusted EPS of $0.06. Liquidity maintained at approximately $149 million.
Product Portfolio Growth
MyRisk demonstrated 11% revenue growth, with strong adoption and payer coverage. Women's Health segment delivered 10% prenatal revenue growth year-over-year.
GeneSight Revenue Increase
GeneSight revenues increased 34% year-over-year, with a volume growth of 10% and improvements in revenue per test.
Strategic Initiatives and Investments
Continued investment in the Labs of the Future program with over $75 million invested, leading to improved operational efficiency and test turnaround times.
---
MYGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MYGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $17.67 | $17.41 | -1.47% |
| Aug 06, 2024 | $25.96 | $26.64 | +2.62% |
| May 07, 2024 | $19.78 | $23.95 | +21.08% |
| Feb 27, 2024 | $23.50 | $21.61 | -8.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Myriad Genetics (MYGN) report earnings?
Myriad Genetics (MYGN) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Myriad Genetics (MYGN) earnings time?
Myriad Genetics (MYGN) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MYGN EPS forecast?
MYGN EPS forecast for the fiscal quarter 2024 (Q4) is $0.03.
---